Helper virus-independent, E1-deleted adenovirus ([E1−]Ad)-based gene transfer vectors exhibit many positive attributes, including a large transgene-encoding capacity, a relative ease of high-titer production to clinical grades, and the ability to infect a wide range of tissue types. Despite the fact that [E1−]Ad vectors are significantly blocked in their ability to replicate (relative to a wild-type Ad), low-level replication and/or gene expression derived from [E1−]Ad vectors can limit their usefulness (2, 18). To overcome this problem, we previously demonstrated that [E1−]Ad vectors incorporating additional deletions in the Ad E2b genes (polymerase and/or pTP) rendered [E1−,E2b−]Ad vectors truly replication incompetent (2, 10, 11). As a result, [E1−,E2b−]Ad vector-derived late gene expression was also significantly diminished, since Ad late gene expression is only initiated after Ad genome replication has occurred (19). Despite the problems associated with Ad replication, a potentially useful Ad vector might be one that can replicate its genome to very high levels after infection of a cell. This feature could be capitalized upon in efforts to either amplify transgene expression encoded by the vector and/or induce cytopathic effects as a consequence of high-level Ad replication and/or infectious virus production. For example, E1a-positive, E1b-deleted ([E1a+,E1b−])Ad vectors have been described; the E1b deletion restricts E1a-dependent vector replication (and generation of infectious vector) to cancer cells only, resulting in their death (3, 9). There is evidence, however, that [E1a+,E1b−]Ad vectors can also replicate in noncancerous cells, potentially limiting the risk/benefit ratio of [E1a+,E1b−]Ad-based cancer therapies (17). In a recent attempt to address the latter concerns, Ad vectors have been developed that are protease deleted (14). Protease-deleted [E1+]Ad viruses can also replicate but are blocked in their ability to produce infectious virus, due to inadequate maturation of viral capsid proteins during the late phase of the Ad life cycle. Importantly, however, both [E1b−] and protease-deleted Ad vectors are fully capable of producing wild-type levels of the Ad late genes once replication has occurred (14). The late genes are numerous and include the hexon, 100K, penton, and fiber proteins. Some of the toxicity normally associated with the expression of these proteins (particularly penton) may potentially limit the overall usefulness of both of these types of replicating Ad vector. It is with these considerations that we have targeted the 100K gene of the Ad for deletion. After Ad replication occurs, transcription is initiated from the major late promoter (MLP), and activation of the MLP results in the generation of the L4 transcript, which encodes the Ad 100K protein. The 100K gene fully encompasses 10% of the Ad genome, reflective of the vital role 100K plays in various aspects of the Ad life cycle. Functions of the 100K protein include the transport of newly synthesized hexon monomers (the major structural protein of the Ad capsid) from the cytoplasm to the nucleus and trimerization of hexon monomers (4). Without this activity, hexon monomers are degraded in the cytoplasm (15). 100K also acts as a “scaffolding platform” for the assembly of virus capsids, although the 100K protein has not been found to be physically incorporated into mature Ad capsids (13). 100K can also interact with a number of RNA transcripts, both vector and host cell derived, preferentially allowing for translation of Ad-derived late-gene transcripts (1, 12, 16). Considering these critical roles, we hypothesized that deletions within the 100K gene might allow for the production of Ad-based vectors with significantly altered characteristics. In this report we now demonstrate that [100K−] vectors can be produced to high titer and that the altered biology of vectors incorporating these deletions might be capitalized upon in several gene therapy applications.